Sign up online today & collaborate
or click here to find out more
Germany-based Hyglos and scientists from the universities of Tübingen, Münster and Munich join forces to develop a phage-based active substance against the dreaded hospital pathogenStaphylococcus aureus.
Their secret is a highly effective protein from bacteria-specific viruses, so-called bacteriophages, that shall rapidly kill the bacteria, which frequently occur in the nose. Due to the specific action of this protein, the natural microflora is maintained. This prophylactic treatment could counteract the spread of methicillin-resistant staphylococcus aureus (MRSA) in hospitals and thereby prevent infections in patients.
“We do like to describe it as a MRSA-killing protein, even if it sounds somewhat sensational”explains Dr. Wolfgang Mutter from Hyglos GmbH.
According to experts, every third person carries the bacterium Staphylococcus aureus in their nose. It is not dangerous in the case of healthy individuals, but quickly becomes a problem if the carrier is admitted to a hospital. The pathogen can then enter into wounds and potentially cause dangerous infections, increasing the risk of spread as a hospital bug. Especially feared are MRSA, because of their resistance to many of the commonly used antibiotics.For more click here